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Abstract: Virus-like particles (VLPs) derived from viral nucleocapsids are an important class of
nanoparticles. The structure, uniformity, stability, and function of these VLPs have attracted scientists
in utilizing them as a unique tool in various applications in biomedical fields. Their interaction
with the innate immune system is of major importance for the adaptive immune response they
induce. The innate immune cells and molecules recognize and interact with VLPs on the basis of
two major characteristics: size and surface geometry. This review discusses the interaction of viral
capsid-derived VLPs with the innate immune system.
Keywords: virus-like particle (VLP); innate immune system; adaptive immune system; Toll-like
receptor (TLR)
1. Virus-Like Particles (VLPs)—Brief Overview
Virus-like particles (VLPs) are supramolecular complexes formed by viral proteins that
self-assemble into capsids resembling real viruses, albeit non-infectious due to the lack of viral genome
packaged within the particle. Such non-infectious particles can be naturally formed during infection or
genetically engineered and produced in large scales in laboratories. Most VLPs are characterized by
stability, together with uniform and repetitive structure that allow diverse applications in the field
of biomedical science. Since their early discovery five decades ago, VLPs led to enormous progress
in the field of vaccine development with seven vaccines approved for humans and several others
in pre-clinical phase or in clinical trials [1,2]. Most VLPs are formed by proteins naturally forming
nucleocapsids and consist of several copies of monomers in quasi-equivalent conformations forming
icosahedral or helical (rod-shaped) structures. The final shape of VLPs usually imitates the symmetry
of the original parental virus but can vary according to the nucleic acid content or biophysical context
during the assembly phase [3].
The virus-like property of VLPs is a potent geometric pathogen-associated structural pattern
(PASP) facilitating their engagement with innate and adaptive immune cells. The exterior and interior
facets of VLPs can be functionalized and modified to enhance their immunogenicity and stability or
to present heterologous antigens (Figure 1). The viral capsids have evolved to preferentially package
their own viral genome. Nucleocapsid-derived VLPs retain this property of packaging nucleic acids,
and since the viral genome is absent, VLPs will package nucleic acids from host cells during the
expression process. Interestingly, these naturally packaged nucleic acids can be substituted by other
anionic polymers to modulate the immune response by engagement of different pattern recognition
receptors (PRRs) [4–6]. The outer surface of VLPs has also been functionalized with heterologous
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antigens by chemical crosslinking, genetic fusion or peptide splicing techniques aiming to enhance the
immunogenicity of coupled antigens [6,7].
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Figure 1. A schematic diagram of nucleocapsid-derived VLPs illustrating some modifications that can 
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2. VLPs Interaction with the Innate Immune System 
VLPs—especially those packaging nucleic acids—are capable of inducing a comparable humoral 
immune response to viruses. This is considered a major advantage of VLPs over attenuated virus-
derived vaccines as it guarantees safety of the vaccines whilst retaining their immunogenicity [8]. The 
immune system in general recognizes and interacts with viral capsid-derived VLPs on the basis of 
two major characteristics, size and surface geometry [2] as discussed next. 
2.1. Drainage of VLP into the Lymphatoid Organs 
The lymphatic system regulates the balance of fluid in the body as well as the trafficking of 
immune cells and antigens to lymphoid organs, in particular lymph nodes (LNs) [9]. The efficient 
draining of antigens and particles from the periphery to the primary and secondary lymphoid organs 
guarantees the encounter of such particles with the relevant immune cells that will initiate the 
immune response. Thus, draining properties of antigens have an important impact on its overall 
immunogenicity [10,11]. 
The diameter of the blind-ended structure of the initial lymphatic vessels is about 10–60 μm. The 
vessels are lined up with single flattened endothelial cells forming valves that ensure the 
unidirectional movement of fluids through and along the lymphatic vessels [12]. Furthermore, the 
initial lymphatic vessels are highly permeable due to the presence of button-like junctions or gaps 
between the endothelial cells [13]. Particulate materials can directly diffuse through the 200 nm pores 
of the lymphatic vessels’ walls with an optimal size between 30–40 nm [14]. VLPs range between 20–
200 nm in size, which allows them to freely drain into the lymphatic system. 
The kinetics of free drainage of viral capsid-derived VLPs has been studied extensively and 
previous data has shown that VLPs with average size of 30 nm can be detected in mice footpads for 
at least 40 min post injection and at the draining LN 2 h post injection [14]. Recently, with the 
advancement of imaging techniques it has been shown that 30 nm VLPs can accumulate at the 
popliteal draining LN in less than 10 min post subcutaneous injection in murine footpads [15]. In 
addition to free lymphatic drainage, VLPs can also be actively transported via specialized cells such 
as skin-derived macrophages and DCs, mainly dermal DCs (dDCs) and Langerhans cells (LCs). These 
cells, especially upon activation, can efficiently squeeze through the button-like junctions of the 
endothelial cells lining lymphoid vessels and migrate through the lymph along a CCL19/CCL21 
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2. VLPs Interaction with the Innate Immune System
VLPs—especially those packaging nucleic acids—are capable of inducing a comparable humoral
immune response to viruses. This is considered a major advantage of VLPs over attenuated
virus-derived vaccines as it guarantees safety of the vaccines whilst retaining their immunogenicity [8].
The immune system in general recognizes and interacts with viral capsid-derived VLPs on the basis of
two major characteristics, size and surface geometry [2] as discussed next.
2.1. Drainage of VLP into the Lymphatoid Organs
The lymphatic system regulates the balance of fluid in the body as well as the trafficking of
immune cells and antigens to lymphoid organs, in particular lymph nodes (LNs) [9]. The efficient
draining of antigens and particles from the periphery to the primary and secondary lymphoid organs
guarantees the encounter of such particles with the relevant immune cells that will initiate the
immune response. Thus, draining properties of antigens have an important impact on its overall
immunogenicity [10,11].
The diameter of the blind-en ed structure of the initial lymphatic vessels is about 10–60 µm.
The vessels are lined up with single flatten d endothelial cells ormi g valves that ensure the
unidir ctio al movem nt of fluids th ough and along the lymphatic vessels [12]. Furthermore, the
initial lymphatic vessels are highly permeable due to the presence of button-like junctions or gaps
between the endothelial cells [13]. Particulate materials can directly diffuse through the 200 nm pores
of the lymphatic vessels’ walls with an optimal size between 30–40 nm [14]. VLPs range between
20–200 nm in size, which allows them to freely drain into the lymphatic system.
The kinetics of free drainage of viral capsid-derived VLPs has been studied extensively and
previous data has shown that VLPs with average size of 30 nm can be detected in mice footpads
for at least 40 min post inje tion nd at the dr ining LN 2 h post inj ction [14]. R cently, with the
advancement of imaging techniques it has been shown that 30 nm VLPs can accumu ate at the popliteal
draining LN in less than 10 min p st subcutaneous injection in murine footpads [15]. In addition to free
lymphatic drainage, VLPs can also be actively transported via specialized cells such as skin-derived
macrophages and DCs, mainly dermal DCs (dDCs) and Langerhans cells (LCs). These cells, especially
upon activation, can efficiently squeeze through the button-like junctions of the endothelial cells
lining lymphoid vessels and migrate through the lymph along a CCL19/CCL21 gradient towards
the draining LN. Previous studies have shown that skin-derived DCs—CD11chiCD40hiCD8− and
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CD11cintCD40hiCD8− DCs—can successfully uptake VLPs after intradermal injection. Both identified
subsets of skin-derived DCs have also been shown to effectively cross-prime cytotoxic T-cells following
VLPs uptake [16]. Even though, CD8+ DCs are usually much more potent in cross-presenting
VLP-derived antigens [17].
In summary, the size of antigen influences the immunogenicity largely by two mechanisms: first,
by allowing the appropriate draining from periphery to secondary lymphoid organs and second by
facilitating the interaction with APCs due to their repetitive surface. VLPs size distribution falls within
the aforementioned optimal range, which explains in part its remarkable immunogenicity.
2.2. Trafficking of VLPs Within Draining LN
In general, particles ranging between 20–200 nm upon reaching the LN are distributed throughout
the different areas of the draining LN. Previous studies have shown that VLPs are detected at the
sub-capsular, medullar and cortical regions of LNs as fast as 2 h post subcutaneous injection. At a
later stage, VLPs are also detected deeper in B-cell follicles bound to follicular dendritic cells (fDCs)
(Figure 2). At 48 h post injection VLPs were distributed in the sub-capsular area, cortex, and para-cortex
of the draining LN and some were inside B-cell follicles [14]. Upon arrival at the draining LN, several
LN residing myeloid cells and B-cells will carry out the active transportation of free VLPs from the
sub-capsular sinuses to B-cell follicles [18–21]. The pattern of distribution of VLPs allows access and
interaction of particles with different cell types in the secondary lymphoid organs, which contributes
to the immune response generated against those particles.
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The predominant subsets of APCs actively up taking viral capsid-derived VLPs in the popliteal 
LN post subcutaneous injection have been recently classified. These cells include the sub-capsular 
sinus (SCS) macrophages CD11b+F4/80+, different subsets of conventional dendritic cells (cDCs) 
including CD8+CD11c+, CD8−CD11b+, and CD8+CD11c+. B-cells characterized by CD45R/B220+ were 
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Figure 2. Distribution of VLPs in the draining LN. VLPs arrive in the LNs by natural drainage in a
cell-free manner or transported by APCs. Upon reaching the sub-capsular sinus of the draining LN,
VLPs will be phagocytized by different APCs and preferentially reach the B and/or T-cell zones. VLPs
endocytosed in the periphery by APCs preferentially reach the T-cell zone in the draining LN for
T-cell priming.
The predominant subsets of APCs actively up taking viral capsid-derived VLPs in the popliteal
LN post subcutaneous injection have been recently classified. These cells include the sub-capsular
sinus (SCS) macrophages CD11b+F4/80+, different subsets of conventional dendritic cells (cDCs)
including CD8+CD11c+, CD8−CD11b+, and CD8+CD11c+. B-cells characterized by CD45R/B220+
were less efficient in up taking VLPs [15] but are likely responsible for their transport to fDCs in B-cell
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follicles [21]. Medullary DCs within lymphoid organs would also participate in the transportation of
antigens by binding them to their surface receptors such as SIGN-R1 (CD209b) [20]. Other studies
have shown that SIGN-R1 and DC-specific ICAM3-grabbing non-integrin receptors (DC-SIGN) have
also a role in antigen transportation and presentation. In addition, DCs can also capture VLPs and
present VLP-derived peptides in the paracortical T-cell zone resulting in the activation of T and
B-cells in the extra-follicular area [22]. Initial studies have shown that skin-derived DCs which have
encountered antigens in the skin preferentially colonize specific areas within the draining LN. dDCs
are known to migrate to the paracortex underneath B-cell zone, whereas LCs migrate and colonize the
inner-paracortex [23]. Therefore, actively transported VLPs by skin-derived DCs either dDCs or LCs
would follow similar migration pattern to T-cell zone and thereby are considered to be key initiators of
T-cell immunity. A study suggested that skin-derived DCs act as initial transporters of herpes simplex
virus (HSV) to non-migratory LN resident CD8+ DCs for effective CTL priming [24].
As described above, the draining and trafficking of VLPs within the immune system and
subsequent interaction with immune cells such as DCs, macrophages, and B cells allow the initiation
of both humoral and cellular immune responses. Details of the immune response to VLPs used as
vaccines will be discussed in the following sections.
2.3. VLPs and Innate Humoral Immune Response
The highly repetitive surface structure of viral capsid-derived VLPs facilitates their interaction
with components of the innate humoral immune system that in turn mediates opsonization and
phagocytosis by APCs (Figure 3). The natural pentameric IgM antibody can efficiently bind to VLPs
via low affinity/high avidity interactions [2,21]. It has been shown that even if the interaction between
a single viral coat sub-unit with a single recognizing element on the multimeric molecule is weak,
the overall avidity of the interactions of the antibodies with the entire VLP would be considerably
stronger thanks to the repetitive surface of the particles [21]. The pentameric IgM alone is not an
efficient direct activator of the opsonization mechanism. However, IgM contributes to the activation of
C1q molecule upon binding. Activation of C1q consequently leads to the activation of the classical
complement cascade initiated by the formation of C1-complex consisting of C1q and serine proteases
C1r and C1s molecules. C1q can also bind directly to the surface of VLPs causing a conformational
change in C1q molecule leading to the activation of classical complement cascade. In our hands,
however, both deficiency in IgM as well as C1q led to a complete failure of VLP-deposition on
fDCs [21]. Such findings indicate that natural IgM binds to VLPs followed by recruitment of C1q.
Interestingly, complement may not always enhance activation of innate cells. Papaya Mosaic Virus
VLPs for example induce marked production of IFN-α in pDCs and complement inhibits rather than
promotes this process [25].
The pentraxin protein family including the short pentraxin C-reactive protein (CRP), serum
amyloid P (SAP) and long pentraxin (PTX3) may also recognize the repetitive structure of VLPs due to
high avidity interactions. SAP, for example, has been shown to bind to influenza A viral particles [26].
This recognition may also result in high affinity binding to C1q molecule and effective initiation of the
classical complement cascade [2]. More research, however, is necessary to study the interaction of the
innate humoral immune system and VLPs.
The hallmark of the immune response induced by VLPs is the induction of high levels of long
lasting humoral responses. In contrast to soluble antigens, the highly organized and repetitive
structure of VLPs promotes crosslinking of BCRs that surpasses the activation threshold and bypasses
the initial need of T-cell help. As a consequence, any antigen exposed on the surface of VLPs in this
same organized and repetitive array will benefit from this viral fingerprint and induce high levels of
humoral responses.
Another important feature of the humoral response elicited by VLPs is the promotion of isotype
switching dependent on direct TLR7 or TLR9 signaling on B-cells [27,28]. Upon BCR-mediated
endocytosis of VLPs, the nucleic acid that is often packaged within VLPs reaches the endocytic
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compartment where it can interact and activate endosomal TLRs, the downstream response leads
to isotype switching of antibodies to IgG2 in mice and IgG1 in humans, the isotypes with higher
effector function.
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Figure 3. VLPs and innate humoral immune response. The repetitive surface of viral capsid-derived
VLPs facilitates their interaction with molecules and components of the innate humoral immune
system. (A) IgM binds the surface of VLPs via low affinity/high avidity interaction. This binding
activates C1q molecules resulting in the initiation of the classical complement cascade. (B) More
speculative, pentraxin protein family members including CRP, amyloid P SAP and PTX3 may also
recognize and bind the repetitive surface structure of VLPs resulting in the activation of C1q molecule
and the initiation of the classical complement cascade.
Furthermore, intranasal administration of VLPs in murine models resulted in strong B-cell
responses and germinal center formation in the spleen. Roaming B-cells in the lungs have been shown
to bind VLPs through their BCR and shuttle them to B-cell follicles within the spleen [29].
2.4. Efficient Presentation of VLPs by Both MHC Pathways
Following the uptake by professional APCs, processed VLPs will be subsequently presented on
MHC molecules. In general, exogenous antigens (endocytosed or phagocytosed) are presented on
MHC-II molec les to trigger the activation of Th CD4+ cells following end som l processing [30].
Endogenous antigen on the other hand are l aded on MHC-I molecules for CD8+ CTLs priming.
The classical source of MHC-I antigens is newly synthesized proteins hich are misfolde and
degraded in the proteasomes. Nevertheless, it has been found that both presentation pathways are
not strictly separated [31] as exogenous antigens can also reach MHC-I presentation pathway in a
process called cross-presentation [32–34]. Cross-presentation can be TAP dependent or independent.
In TAP dependent pathways the antigen will be taken by endosomes and leak to the cytosol afterwards
(endosome to cytosol pathway). In TAP independent pathway, peptide load MHC-I in the endosomes
directly as an exchange process under acidic conditions, such a process may be referred to as direct
endosomal loading pathway [34–36]. The ability of exogenous VLPs to be presented on MHC-II
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molecules to generate protective IgG antibody titers via activating Th cells has been previously
documented to be highly efficient and biologically relevant. Cross-presentation on MHC-I molecules
has also been studied extensively and has been documented for tumor cells, necrotic cells, apoptotic
cells, viruses, and VLPs [34,37–39]. The efficiency of VLPs presentation via MHC-I vs. MHC-II
molecules in vivo was quantified [34]. This was done by using immunodominant MHC-I or MHC-II
antigens derived from lymphocytic choriomeningitis virus (LCMV) linked to VLPs. The results
indicated that cross presentation on MHC-I molecules for VLPs containing antigens was only 1 to
10-fold less efficient than classical presentation on MHC-II molecules. This finding indicates that VLPs
as exogenous particles can be loaded efficiently onto both MHC molecules [34]. It has been reported
that exogenous antigens can reach MHC-I molecules in CD8+ DCs only while CD8− DCs present them
on MHC-II molecules [40].
However, this dichotomy hypothesis was not supported in other studies which have shown that
both CD8+ and CD8− DCs can efficiently present VLP-derived antigens on MHC-II molecules, however
only CD8+ DCs were able to cross-present VLPs derived peptides. This implies that VLPs presentation
on MHC-II molecules to CD4+ T-cells is not restricted to a specific DCs subset but cross-presentation to
CD8+ T-cells is usually restricted to a CD8+ DCs subset [17].
2.5. Packaging VLPs with Innate Immune-Modulators
Many VLPs, including Norovirus, Papaya Mosaic Virus, Human Papilloma Virus and Qβ-derived
VLPs activate innate cells through various means [25,36,41]. An important reason for the ability of
RNA virus nucelocapsid derived VLPs to activate DCs and B-cells is the fact that they package RNA.
Even though these VLPs lack infectious genome, they usually package nucleic acids (RNA) during
the assembly process in host cells. Moreover, VLPs can be efficiently packaged in vitro with a range
of charged polyanionic sequences such as RNA with specific secondary modification or CpGs, for
instance. Nucleic acids are recognized and can activate PRRs, which modulates and alters the adaptive
immune response [42]. VLPs are reportedly inefficient at inducing strong antigen-specific cytotoxic
response, however the addition of other certain classes of PRR ligands such as non-methylated CpGs
can efficiently activate TLR9 leading to robust Th1 and CTL response [43]. Non-methylated CpGs
are classified into three different categories according to their structure and the immune response
they induce. In general, CpGs of all three classes can activate inflammatory cytokines as well as
type-I IFN at different levels upon stimulation of TLR9 in plasmacytoid dendritic cells (pDCs) [44].
Class A CpGs are characterized by the presence of phosophodiester poly G sequence at the 5′ and
3′ ends as well as an internal palindrome sequence in the central portion. Class A CpGs are capable
of producing large amounts of type-I IFN in particular by pDCs [45]. In contrast, class B CpGs
characterized by a full phosphorothioate backbone can induce type-I IFN production to a lesser extent
than class A. However, class B CpGs is capable of stimulating pro-inflammatory cytokines, such as
IL-12 [46]. The homologous TLR7/8 expressed within the endosomal compartments of APCs can
recognize guanine nucleotide-homologues such as loxoribine, R848, imidazouinoline components,
and uridine/guanosine rich ssRNA [47]. Free RNA is usually subjected to degradation by the RNase
enzyme in the extracellular spaces. Accordingly, the possibility that free RNA will reach the endosomal
compartments of APCs to interact with and activate endosomal TLRs is quite low. Therefore, packaging
ssRNA into VLPs protects it from extracellular RNase and results in efficient activation of TLR7/8.
TLR3 is mainly expressed in cDCs but not pDCs and recognizes dsRNA. The synthetic RNA sequence
poly I:C, leads to a type-I IFN response and production of proinflammatory cytokines [48]. It has been
reported that VLPs formulated with Poly I:C can lead to an improved CTL response [49].
In general, recognition of ssRNA, dsRNAm or CpGs packaged into VLPs by endosomal TLRs will
result in the activation of signaling pathways that are essential for the expression of different genes
required to initiate the inflammatory responses (Figure 4). The process starts by ligand-induced TLR
dimerization to bring TIR domains in close proximity and facilitate the recruitment of protein kinases.
This will activate several major transcription factors such as NF-κB, AP-1, IRF3, and IRF7 [50–53].
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NF-κB and AP-1 will stimulate the expression of several inflammatory genes including cytokines (TNF
and IL-6), chemokines (CCL2 and CXCL8), some endothelial adhesion molecules such as E-selectin
and other costimulatory molecules including CD80 and CD86. On the other hand, IRF3 and IRF7 are
responsible for the expression of type-I IFN α/β genes. TLR7 and TLR9 are MyD88-dependent and
IRF-independent signaling pathways, and both are capable of activating NF-κB and IRFs transcription
factors. In contrast, TLR3 acts through the activation of TRIF which will induce IRF3 responsible for
the expression of type-I IFN [52,53].
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Figure 4. Packaging VLPs with innate immune-modulators. Viral capsid-derived VLPs packaging
different nucleic acids can be efficiently internalized by APCs. The packaged nucleic acids will
be released in the endosomal compartment of the cell following degradation of VLP-protein shell.
ssRNA is TLR7/8 ligand, CpGs is TLR9 ligand and dsRNA is TLR3 ligand. Ligand induced
TLR-dimerization activates transcription factors such as NF-κB, AP-1, and IRFs and induces the
expression of inflammatory genes and type-I IFN genes.
Apart from TLRs, other PRRs and nucleic acid sensors have also been reported to play a role in
the immune response elicited by VLPs. RIG-I and the stimulator of IFN genes protein (STING) induces
significant levels of type-I IFN upon viral infection mediating autocrine and paracrine signaling [54].
Activation of STING results in the activation of different transcription factors including STAT6 and
IRF3 [55]. Although STING and RIG-I mediated responses are often associated with intermediates
of viral replication, there are evidences that envelo e derived VLPs may fuse with cell-membranes
which can be sen d by the innate immune cells in murine and human cells. This fusion c n ac ivate a
STING-de ende t signaling path ay which induces the formation of Tank Bindi g Kinase Complex
protein (TBK1) which also involves IRF3. This pathway will finally activate the expression of type-I
IFN as well as other IFN stimulating genes (ISGs) [56]. Recently, it has been shown that by including
cyclic di-nucleic (CDNs) acids into VLPs, the CTL response against tumors was improved in a cGAS
and STING dependent manner in comparison to the effect observed with the addition of the CDNs
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alone [57]. This highlights the benefits of packaging of nucleic acid into VLPs, which has consistently
shown to improve pharmacokinetics of the adjuvants and the observed immune response.
2.6. Important Considerations on VLP Based Vaccines
VLPs had been consistently successful at inducing protective immune responses in various
pre-clinical models and clinical trials both for infectious and non-infectious diseases. The field had
started employing naturally occurring VLPs during infection as vaccines, as exemplified by the
Hepatitis B vaccine [58] and has now expanded to well stablished platform VLPs such as the well
described Qβ [59], AP205 [41], MS2 [60] to name a few, that had been applied as vaccines against
diseases ranging from nicotine dependency [61] to asthma [62] and hypertension [63].
The success of this approach relies on presenting heterologous antigens to the surface of model
VLPs and in this manner, conferring the highly immunogenic viral fingerprint to those antigens.
There are two main methods for presentation of heterologous antigens: chemical crosslinking or
genetic fusion. The choice of method will impact the quality of the immune response as it will affect
the valency of decoration of the particle with the antigen and the overall stability of the vaccine.
For that reason, small changes in the crosslinking method must be closely evaluated as it can directly
affect immunogenicity.
A second important consideration for VLPs is the expression system of VLPs. During the assembly
phase VLPs will randomly pack host derived components that can have an unbeknownst impact in
the immune response. Thus, the same VLP can exert different immune responses depending on the
manufacturing process. This is an important consideration when comparing results across different
groups and when scaling up the manufacturing process.
2.7. Challenges for VLP-Based Vaccine Development
As is common to other vaccine development platforms, there are several challenges that should
be considered for successful development of VLP-based vaccines. There are some risks that are specific
to the VLP-platform technologies and some risks that are related to the specific vaccine candidates.
Challenges specific to VLP-based vaccine platforms
• Even though several VLP-based vaccines are on the market, some more recent candidates struggle
with stability. In addition, no vaccine that displays foreign epitopes has made it to the market so
far. Hence, real-life, market PoC for such vaccines is missing. While there is no a priori reason
that this should not be possible, it may still be perceived as a potential risk.
• Most if not all nucleocapsid VLPs derived from RNA viruses package RNA from the production
host cells. This may need an additional Quality Control effort.
• If epitopes are to be fused into VLPs, this can create substantial problems, as VLPs may not
assemble anymore.
Challenges for individual vaccines
• The selected epitope may not be protective
• Induced immune responses may be too low
• The selected indication may sound interesting but does not attract interest from industry and/or
the end-customer
3. Conclusions
The highly immunogenic properties of VLPs are a direct consequence of the viral fingerprint
retained from the parental viruses. Such properties can be summarized by size, surface geometry,
and ability to package nucleic acids. VLPs immunogenicity can also be extended by presenting
heterologous antigens on their surface.
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